Furthermore, we treated the cells with a highly selective PLK1 inhibitor, volasertib, which potently reduced cell viability in six cancer cell lines with a significantly lower IC50 value than that in normal cell lines (Figure 2G,H). This evidence concerns the gene PLK1 and cancer.